Calithera Biosciences Initiates Phase 1b Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis

NEXT STORY
Menarini Silicon Biosystems Partners with OpGen to Broaden Distribution of CELLSEARCH Platform in North America
PREV STORY
Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Immunomedics Receives Edison Patent Award From Research & Development Council of New Jersey for the Fourth Time

MORRIS PLAINS, N.J., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today announced ...

author_avatar
NASDAQ Market News

Cempra Presents Data at ECCMID Highlighting Need for New CABP Therapies and Activity of Solithromycin in Key Population Groups

CHAPEL HILL, N.C., April 21, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage ...

author_avatar
NASDAQ Market News

Novartis drug crizanlizumab shown to prolong time to patients’ first sickle cell pain crisis in subgroup analysis of SUSTAIN study

Investigational therapy crizanlizumab (SEG101, formerly SelG1) approximately doubled the time to first on-treatment sickle ...

author_avatar
NASDAQ Market News